Full-Time

Sales Manager

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$183.2k - $274.8k/yr

Chicago, IL, USA + 2 more

More locations: Phoenix, AZ, USA | Denver, CO, USA

Remote

Travel up to 75% is required, including some evenings and weekends.

Bachelor's, MBA

Category
Sales & Account Management (1)
Required Skills
Microsoft Office
CRM
Word/Pages/Docs
Business Analytics
Excel/Numbers/Sheets
Microsoft Outlook

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • A minimum of 10 years of progressive experience in biotechnology or pharmaceutical sales and sales leadership is required.
  • A minimum of 5 years of successfully leading sales teams, or equivalent experience, with documented success in exceeding goals over time is required.
  • A minimum of 6 years of epilepsy leadership experience is required.
  • Experience in leading biotechnology or pharmaceutical product launches, preferably in rare disease, is required.
  • Academic and/or institutional experience is required.
  • Prior experience working with local and national patient advocacy groups is required.
  • Rare disease and/or epilepsy experience is required.
  • Successful product launch experience is required.
  • Exceptional leadership, clinical, and business acumen, learning agility, performance management, communication, and written and verbal communication skills are required.
  • High proficiency in Microsoft Office, including Word, Excel, PowerPoint, and Outlook, is required.
  • The candidate must be able to travel up to 75% and have a history of managing large geographic areas.
  • The candidate must hold a bachelor's degree.
Responsibilities
  • Directly lead and manage a team of Neurology Account Managers and Care System Liaisons, including recruiting, hiring, developing, coaching, and evaluating team members.
  • Develop, lead, and execute a local market sales plan with specific goals and targets through different stages of the product life cycle, including launch and growth.
  • Create and maintain a people-valued culture driven by shared values and patient-focused performance.
  • Inspire and unite the team toward a common vision through authentic leadership and an agile approach.
  • Foster an entrepreneurial culture focused on ownership and accountability, and establish open and honest communication with subordinates, peers, and senior leadership.
  • Demonstrate knowledge of the disease state, products, customers, rare or orphan drug market, competitive products, and broader healthcare marketplace.
  • Identify and establish relationships with key and emerging thought leaders and customers, and engage healthcare professionals as needed.
  • Develop the sales team's skills, knowledge, and behaviors through coaching, development training, and related activities.
  • Collaborate with leaders in Market Access, Marketing, Sales Training, Medical Affairs, Patient Access, Government Affairs, and Compliance to achieve shared business objectives compliantly.
  • Analyze, interpret, and leverage sales analytics, customer relationship management reports, business statistics, and customer feedback to develop strategic business plans and execute them successfully.
  • Manage promotional and travel-and-expense budgets in accordance with company compliance policies.
  • Conduct company business in accordance with applicable regulations and company policies and procedures.
  • Maintain high ethical and performance standards with contacts in the medical and pharmaceutical community.
  • Foster and maintain a culture of compliance by modeling integrity and requiring the sales team to follow legal, ethical, and procedural standards.
  • Attend regional and national meetings, conferences, and advocacy support events, including some evenings and weekends.
Desired Qualifications
  • Experience in product marketing, sales training, commercial operations, or equivalent is preferred.
  • Strong business relationships in the epilepsy community are preferred.
  • An MBA or other advanced degree is preferred.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue hit $1.21 billion, and guidance rose to $4.75 billion.
  • Zepzelca grew 60% in Q1 2026 on first-line maintenance adoption.
  • Zanidatamab gained FDA Priority Review, positioning Jazz for a near-term oncology launch.

What critics are saying

  • Granules settlement allows a Xywav generic under certain conditions after March 2026.
  • Jazz still carries $4.35 billion debt, with $1.0 billion 2030 notes now exchangeable.
  • Zanidatamab faces an August 25, 2026 PDUFA; rejection cripples launch expectations.

What makes Jazz Pharmaceuticals unique

  • Xywav dominates narcolepsy and idiopathic hypersomnia through low-sodium oxybate differentiation.
  • Jazz owns scarce neurology and oncology assets, including Epidiolex, Zepzelca, and Ziihera.
  • Actio acquisition on August 10, 2026 extends its rare-epilepsy precision medicine franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.

Yahoo Finance
Aug 10th, 2026
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, adding KCNT1+ epilepsy therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.

Yahoo Finance
Aug 5th, 2026
Jazz Pharmaceuticals hits $1.2B quarterly revenue, raises full-year guidance to $4.75B on oncology surge

Jazz Pharmaceuticals reported record quarterly revenue of $1.2 billion for Q2 2026, marking a 16% year-over-year increase driven by double-digit growth across all key promoted brands. The oncology portfolio grew 32% year-over-year, supported by rapid adoption of Zepzelca in first-line maintenance and the successful launch of Modeyso. Xywav demonstrated 13% revenue growth as its low-sodium profile continues to differentiate it from high-sodium generics. The company raised its full-year revenue guidance to $4.60 billion–$4.75 billion. Jazz anticipates the 25 August PDUFA date for zanidatamab in first-line HER2-positive gastric cancers, with commercial teams prepared for immediate launch. The company is leveraging its biliary tract cancer infrastructure to support the zanidatamab rollout. Non-GAAP adjusted gross margin declined slightly due to higher sales mix of royalty-bearing products.

Yahoo Finance
Jun 23rd, 2026
Jazz Pharmaceuticals' lung cancer drug fails trial but investors spared as focus shifts to first-line treatment

Jazz Pharmaceuticals' phase 3 trial evaluating Zepzelca in second-line small-cell lung cancer failed to meet its primary endpoint of overall survival. However, the setback's impact may be limited as Zepzelca's commercial focus has already shifted. In 2025, the FDA granted full approval to Zepzelca combined with Roche's Tecentriq as a first-line maintenance treatment for extensive-stage small-cell lung cancer. That approval demonstrated a 46% reduction in disease progression risk and a 27% reduction in death risk compared with Tecentriq alone. Zepzelca sales increased 60% year over year to approximately $101 million in Q1 2026, driven by first-line maintenance adoption. The drug contributed only 7% of Jazz's total 2025 revenue of $4.3 billion, with neurological medications Xywav and Epidiolex generating significantly larger sales.